Valuation: Plasmatech Biopharmaceuticals Inc

Market Cap 40Cr 35Cr 32Cr 30Cr 56Cr 3.82TCr 58Cr 386.84Cr 151.72Cr 1.88TCr 150.03Cr 146.75Cr 6.49TCr P/E 2026 *
-9.49x
P/E 2027 * -100x
Enterprise Value 40Cr 35Cr 32Cr 30Cr 56Cr 3.82TCr 58Cr 386.84Cr 151.72Cr 1.88TCr 150.03Cr 146.75Cr 6.49TCr EV / Sales 2026 *
6.1x
EV / Sales 2027 * 2.96x
Free-Float
79.45%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Plasmatech Biopharmaceuticals Inc

Manager TitleAgeSince
Chief Executive Officer 50 15/10/2021
Director of Finance/CFO 42 14/03/2022
Chief Tech/Sci/R&D Officer - 20/10/2025
Director TitleAgeSince
Director/Board Member 58 01/03/2006
Director/Board Member 64 25/03/2021
Director/Board Member 63 19/04/2021
Change 5-day change 1-year change 3-year change Capi.($)
-0.22%+2.04%+16.79%-8.03% 6.76TCr
-0.63%-7.39%+37.82%+199.82% 5.16TCr
+0.36%+40.00%+40.00%+40.00% 4.3TCr
+0.95%-1.13%-49.27%-53.03% 4.09TCr
+4.96%+0.27%+55.75%-24.80% 2.94TCr
-1.85%-18.08%+99.20%-47.07% 2.71TCr
-2.12%-1.20%+66.54%+84.42% 2.33TCr
+1.46%+3.96%+10.55%+179.35% 1.99TCr
-2.12%-3.92%+61.37%+130.60% 1.69TCr
Average +0.13%-2.60%+37.64%+55.70% 3.55TCr
Weighted average by Cap. +0.17%-2.32%+31.01%+47.10%

Financials

2026 *2027 *
Net sales 6.55Cr 5.75Cr 5.32Cr 4.9Cr 9.26Cr 627Cr 9.44Cr 63Cr 25Cr 307.91Cr 25Cr 24Cr 1.06TCr 13Cr 12Cr 11Cr 10Cr 19Cr 1.29TCr 19Cr 130.65Cr 51Cr 634.26Cr 51Cr 50Cr 2.19TCr
Net income -4.23Cr -3.71Cr -3.43Cr -3.16Cr -5.97Cr -404.42Cr -6.09Cr -41Cr -16Cr -198.6Cr -16Cr -16Cr -685.87Cr -21.01L -18.43L -17.07L -15.71L -29.71L -20Cr -30.28L -2.03Cr -79.79L -9.88Cr -78.9L -77.18L -34Cr
Net Debt - -
Logo Plasmatech Biopharmaceuticals Inc
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. The Company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa. Its fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. Its development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Its AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its pipeline programs include ABO-504 (Stargardt disease), ABO-503 (X-linked retinoschisis), ABO-505 (autosomal dominant optic atrophy), UX111 (Sanfilippo Syndrome Type A (MPS IIIA)), TSHA-102 (Rett Syndrome), and TSHA-118 (Infantile Batten Disease (CLN1 Disease)).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-